The FDA approved the use of GlaxoSmithKline's breast cancer drug Tykerb in combination with Novartis' Femara to treat hormone- and HER2-positive advanced breast cancer in postmenopausal patients under hormonal therapy. A study showed that cancer progression was suppressed for 35 weeks in women using Tykerb and Femara together, compared with 13 weeks for those who received Femara alone.

Full Story:

Related Summaries